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Abstract
Streptococcus pneumoniae is a prevalent human pathogen associated with pneumonia. It is
estimated that approximately 1 million people around the world die each year, specifically with
young children and the elderly comprising a significant portion. Currently, antibiotics can treat
the infection but individuals such as the young or elderly are more susceptible to bodily damage
from symptoms, such as pneumonia, meningitis, and sepsis, thus require more preventive
measures. As a result, vaccinations are a key solution to providing effective protection against
infectious pathogens. Presently, two vaccinations exist in the market: PPSV23 and PCV13, which
only protect against select 23 or 13 serotypes respectively of Streptococcus pneumoniae out of
the possible 90. Researchers are searching for alternative antigenic markers conserved
throughout the multitude of serotypes to formulate cross-protective vaccinations. One such
proponent is known as Pneumococcal Surface Protein A (PspA) which is a surface protein
conserved throughout most serotypes and a potential candidate as a subunit vaccine against
Streptococcus pneumoniae. To increase the immunogenicity of PspA for long term and effective
protection, this study utilizes Cholera Toxin B (CTB) as an adjuvant to effectively increase
vaccine efficacy. We assessed the efficacy of the subunit vaccine, PspA, administered
intranasally (i.n.) in conjunction with CTB as an adjuvant. Our results indicated increased
survival in mice immunized with both PspA and CTB accompanied with reduced lung bacterial
burden, increased levels of S. pneumoniae-specific IgG subclass antibodies, increased cytokine
production, and a reduced acute inflammatory response.
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1. Introduction
1.1 Streptococcus pneumoniae: An Overview
Pneumonia is a respiratory infection triggered via a multitude of viruses, bacteria, and fungi.
Pathogens proliferate within the alveoli sacs of the lungs initiating a strong immune response by
the body. Elevated levels of inflammation within alveoli of the lungs may induce large amounts
of pus and fluid to form resulting in the reduction of the lung's capacity to successfully absorb
oxygen within the body (CDC http://www.cdc.gov, 2015). According to the Centers of Disease
Control, Pneumonia is the leading cause of bacterial meningitis for children under the age of five
in the United States as many of these children do not possess a fully developed immune system
nor bodily endurance to cope with the disease (Bitsaktsis et al., 2011). Elderly individuals and
those suffering from immune deficiencies are also at a higher risk of contracting pneumonia
(CDC http://www.cdc.gov, 2015). Although there are several viral factors such as Human
Parainfluenza virus and Respiratory Syncytical Virus that may result in pneumonia, it is the
bacterial pathogen Streptococcus pneumoniae that it is the focus of this study.
Streptococcus pneumoniae is a gram positive, facultative anaerobic extracellular bacteria
that is a very prevalent human pathogen with high morbidity rates among youths, elderly, and
generally immunocompromised individuals (Bitsaktsis et al., 2011). The bacteria is transmitted
directly from carrier to carrier through respiratory droplets resulting in several infectious diseases
ranging from pneumonia, otitis media, meningitis, or sepsis (CDC http://www.cdc.gov, 2015;
Seo, et al., 2001). Upon contracting the disease, symptoms such as coughing, fever, and chest
pains quickly begin to onset after one to three days (CDC http://www.cdc.gov, 2015). Although
average human adults possess adequate immune defenses to resist infection, medications such as
antibiotics are available to treat the infection and prevent further damage to the host. However,
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Streptococcus pneumoniae can be far more life threatening to individuals with preexisting
infections or immune compromised systems due to age or genetic disorders (CDC
http://www.cdc.gov, 2015). As a result, vaccine strategies are ideal routes of preventing
pneumococcal infections and providing long term protection against potential future infections.

1.2 Vaccinations and relevance to Streptococcus pneumonia
Vaccinations originated from the work of Edward Jenner with his work on the small pox
vaccine and further expanded by other notable researchers such as Louis Pasteur and his work
with attenuated rabies viruses. Since then, vaccines have become the highlight of medical
research and still remain as a primary means of long term protection against infectious diseases
(Owen et al., 2009). Vaccines specifically activate the adaptive immune system to achieve
protection by introducing an antigen into the host system. Vaccine strategies may consist of a
variable selection of antigenic determinants ranging from an attenuated form of the whole
pathogen, an inactivated form of the pathogen, a subunit form vaccine of a specific
macromolecule originating from the pathogen, recombinant vectors originating from the
pathogen, or DNA vaccines consisting of the plasmid DNA that encodes the antigenic proteins
(Owen et al., 2009). Selection of the vaccine strategy is relative to the properties of the pathogen
itself ranging from route of infection, virulence, immunogenicity of antigenic determinants, and
potential risks to the host. The study primarily focuses on subunit vaccinations since most
vaccine strategies against Streptococcus pneumoniae comprise of subunit vaccinations.
Streptococcus pneumoniae consist of over 90 serotypes that vary from one strain to next
via each serotype’s unique capsular makeup (Seyoum et al., 2011). Serotype variation prevents
the infected host from acquiring specific immunity against the entire species so that a new
serotype can re-infect the same host. As a result, research has been focused on identifying key
6

surface proteins and polysaccharides that are conserved throughout the majority of serotypes
within Streptococcus pneumonia to produce effective protection against the varying serotypes
(Ferriera et al., 2009). The current market utilizes a polysaccharide based conjugate vaccine with
two most popular being 23-valent pneumococcal polysaccharide vaccine (PPSV23) which is
commonly administered to adults/elderly and the more tolerable Pneumococcal conjugate
vaccine (PCV13) that is more frequently administered to youths. PPSV23 contains twenty three
common pneumococcal polysaccharide antigens and PCV13 contains thirteen common
pneumococcal polysaccharide antigens which elicit an effective immune response resulting in
long-term protection. PPSV23 possessing the broadest range of serotype protection is estimated to
possess an efficacy of around 60 to 80% in adults sixty five years and older (Kawakami, 2016;
CDC http://www.cdc.gov, 2015). However, the cost of isolating all twenty three polysaccharides
and producing these vaccines factors into limited distribution within the population. Also,
PPSV23 is only commonly administered to adults while the more tolerable PCV13 is more
commonly administered to children which protects against significantly less serotypes of
Streptococcus pneumoniae (Seyoum et al., 2011). Secondly, the route of administration is
intramuscular which is not the common infection route of Streptococcus pneumoniae and thus
may produce a lower immune protection compared to that of an intranasal administration which
has been shown to produce a more effective vaccine (Bitsaktsis; Badabadjanova et al., 2015).
Also the cost and ease of intranasal vaccinations versus that of intramuscular presents a better
alternative for vaccinating populations in mass (Ferreira, 2009).

1.3 Route of Vaccination and Antigen Immunogenicity against Streptococcus pneumonia
Streptococcus pneumoniae route of infection most commonly involves the intranasal
pathways of the host and ultimately affects the respiratory pathways of the organism and
7

sometimes resulting in death from three major symptoms. Pneumonia occurs from excess fluid
accumulation within the lungs preventing oxygen from entering the bloodstream, sepsis as a
result of excessive Streptococcus pneumoniae entering the blood stream, or meningitis resulting
from infection within the surrounding brain or spinal fluid. Initially, the pathogen is typically
spread through mucus droplets created by an infected host and transferred to an uninfected one
through touch or airborne. The path of infection plays a vital role in determining the route of
immunization and ultimately increasing overall immunogenicity of the vaccine (Dockrell et al.,
2012; Seo, J., 2002 ). In the case of Streptococcus pneumoniae, an intranasal route of vaccination
has strong immunogenicity thereby eliciting effective and long term protection against said
pathogen (Bitsaktsis et al., 2009).
Pneumococcal Surface protein A (PspA) is a protein that exists on the outer surface of
Streptococcus pneumoniae on the cell wall. PspA is located on the cell wall and conserved
throughout most strains of pneumococci (Bitsaktsis et al., 2011; Hollingshead et al., 2006) and
thus a primary candidate for providing broad range protection from all serotypes of
Streptococcus pneumoniae (Gor et al., 2004). Its role within the pathogen is twofold, it plays a
vital role in virulence during infection and enables Streptococcus pneumoniae to evade
phagocytosis by preventing complement deposition onto its surface (Ferreira et al., 2009; Kono
et al., 2011). The typical immune response to an extracellular pathogen is a humoral response in
conjunction with activation of the complement system upon contact of the pathogen allowing
deposition of the complement factor C3b onto the cellular surface of the pathogen. Complement
factor C3b is important because it opsonizes a pathogen which ultimately leads to phagocytosis
of the bacteria by antigen presenting cells (APC) such as macrophages, which then sequentially
release pro-inflammatory cytokines recruiting additional leukocytes to the site of infection
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(Owen et al., 2009; Ren et al., 2012). APCs also serve a role presenting the pathogen to T cells,
enabling the initiation of an adaptive immune response. Activation of the adaptive portion of the
immune system will target the pathogen specifically. In the case of an extracellular bacterium
such as Streptococcus pneumoniae, the activation of B cells then switch into antibody producing
plasma cells or memory cells providing long term protection against that specific pathogen
(Kono et al., 2011; Gor et al.,2005).

1.4 Cholera Toxin B adjuvant
Cholera Toxin (CT) is the primary virulence factor for the bacterium Vibrio cholera and a
key component in the infectious disease of Cholera. CT can be divided into two subunits;
Cholera Toxin A (CTA) and Cholera Toxin B (CTB). The first subunit, CTA, provides the toxic
and disease function of the two subunits. The second subunit, CTB, provides the anchoring
mechanism for CT by attaching the subunits to a cell (Baldauf, 2015). Cholera Toxin B (CTB)
has been shown to be an effective mucosal adjuvant that is shown to induce increased antibody
production and thus provide enhanced vaccination protection when combined with a mucosal
pathogen (Bitsaktsis et al., 2009). CTB lacks inherent dangers associated with Cholera pathogen
as it lacks the toxic A subunit which causes cellular damage to the host. As a result, CTB is now
regarded as a potentially effective vaccine adjuvant for eliciting effective protection against
target pathogens. In the case of Streptococcus pneumoniae, there have been previous studies that
show the potential increase in immunological protection when utilizing CTB as the adjuvant
(Kono et al., 2011).
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1.5 Immune System: Humoral Immunity
Humoral immunity is integral for eliciting effective protection against extracellular
pathogens. The innate immune system by itself acts as a deterrent to most pathogens from
damaging the host body. It utilizes a range of lymphocytes in conjunction with Toll Like
Receptors inducing a generalized inflammatory response to most threats (Owen et al., 2009;
Seyoum et al., 2011). However, this system possesses limitations and may be unable to
successfully neutralize or prevent certain pathogens from successfully entering into a host and
potentially inducing system wide damage. As a result, the secondary adaptive immune system
possesses the capability of specific immunological targeting against invasive pathogens that
escaped the innate immune system's broader protection. Specific antigen presenting cells (APCs)
possess the vital role of showing antigens to T cells and providing the necessary secondary signal
required to fully activate any naïve B or T cell and thus eliciting specific immunity against the
target antigen.

1.6 Significance of Immunological Proteins: Cytokines
There are several key immunological cytokines involved in effective immunological
protection. Previous studies have shown correlation between altered levels of immunological
cytokines during infection demonstrate immunological functions that are occurring during an
immunological response towards infection. Interleukin (IL)-2 is produced via activated T cells
which further stimulate proliferation of other T-cells and B-cells within the host. IL-2 also
enables activation of Natural Killer (NK) cells in the site of infection. IL-4 is also secreted via
mast cells, basophils, and activated T cells, particularly via type 2 T helper cells (TH-2) which
are a subset of T cells. IL-4 also leads to the stimulation and proliferation of B cells indicating
immunological shift towards humoral immunity. IL-6 is produced and secreted via T and B cells,
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macrophages, and numerous other support cells. IL-6’s main function is to regulate the B and T
cell functions. IL-6 also induces inflammation at the site of infection inducing initial innate
immune response and ultimately the shift towards adaptive immune responses (Owen et. al,
2009). Interferon gamma (INF-γ) is primarily produced primarily by TH-1 cells, some CD-8 T
cells, and NK cells. INF-γ induces a class in antibody production towards the IgG subclasses.
Secretion of INF-γ also activates macrophages which further propagates a shift towards Major
histocompatibility complex (MHC) class 2 expression thusly promoting antibody mediated
humoral immunity. Tumor necrosis factor (TNF) - α plays an integral role in cellular apoptosis
and inflammatory functions by being primarily produced via activated macrophages. An over
expression of TNF-α can result in prolonged inflammation ending in damaged host tissue.
Specifically, TNF-α ligand binds to receptor TNF-R1 that possesses an intracytoplasmic death
domain (DD). The binding between TNF-α and TNF-R1 retains the option of either inducing
cellular apoptosis or survival. (Micheau et al.., 2003)

1.7 Significance of Immunological Proteins: Antibodies
Immunoglobulins play a vital role in conjunction with the adaptive branch of the immune
system to elicit humoral immunity against specific foreign pathogens (Ren et al., 2012).
Immunoglobulins or antibodies are divided into two main portions (Janeway et al., 2001). The
variable region of the antibody is randomly generated upon B cell maturity within the bone
marrow and serves as the attachment point between the immunoglobulin and the specific antigen
that a pathogen possesses. This allows antibodies to possess a wide range of many varying
antigenic sites that are unique to each B cell no matter the pathogen that enters the host body.
The second region, or Fc region or receptor, consists of a constant domain that possesses an
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effector function for the host leukocytes. The function of the Fc receptor stimulates leukocytes
into phagocytosis of the antibody attached pathogen or can stimulate antibody-dependent cellmediated cytotoxicity (ADCC) (Owen et al., 2009). Stimulation by antibodies on leukocytes also
causes increased secretions of immunological cytokines that further promote immunological
functions such as inflammation, leukocyte recruitment, and proliferation. The combination of
cytokines in conjunction with leukocytes induces inflammation and initiates an immune response
against a pathogen.
The most numerous and prevalent immunoglobulin in sera is the isotype IgG. IgG plays a
vital role in humoral immunity for its opsonizing properties allowing phagocytosis of a pathogen
or through ADCC with NK cells. Furthermore, it has the ability to activate the complement
system which further propagates an immune response against a specific antigen (Vidarsson et al.,
2014; Owen et al., 2009). IgG consists of four subclasses; IgG1, IgG2, IgG3, and IgG4 which
vary based on their effector functions and slight structural differences, particularly in the hinge
region. Presently, the focus of this research examines the presence of IgG1 and IgG2c and their
immunological importance against S. pneumoniae. IgG1 is predominant in compliment fixation
and associated with TH-2 activation while IgG2c facilitates more of an ADCC role and
connected with a TH-1 interaction (Petrushina et al., 2003; Owen et al., 2009; Dahlgren et al.,
2015). The presence of IgG1 and IgG2c combined with determined concentrations of type one
and type two cytokines is utilized to subsequently determine the response of TH-2 and TH-1.
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Figure 1 : TH-1 -TH-2 Relationship- Both TH-1 and TH-2 leukocytes possess the ability to elicit
humoral immunity by activating naive B-Cells. Secretion of IL-4 stimulates TH-2 cells to activate B
cells in producing IgG1 while secretion of INF-γ stimulates TH-1 in the creation of Immunoglobulin
IgG2c.
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The objective of this investigation was to determine if the subunit PspA vaccine
combined with the adjuvant CTB created a potent vaccine that provided effective protection
against A66.1 strain of Streptococcus pneumonia (serotype 3). This protection was correlated
with reduced lung bacterial burden, increased S. pneumoniae-specific antibody production,
increased type 1 cytokine secretion during infection, and reduced overall inflammation.
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2. Materials and Methods
2.1 Bacterial Strains and Culture Techniques
Todd Hewitt broth was prepared by suspending 37g into 1000 mL of DiH2O, mixing well
until dissolved, and then filtering the media via a vacuum filtration system at 0.22 um. The
media was then refrigerated at 4° C upon usage.
Streptococcus pneumoniae strain A66.1 was procured from New York Albany Medical.
A66.1 was streaked onto a sheep blood agar plate and incubated at 37° C with 5% CO2 for 18
hours. Two colonies were removed from the plate and mixed into 3 mL of Todd Hewitt Broth
(THB) and incubated at 37° C with 5% CO2 for 8 hours on a shaker. Removed 200 μL of culture
and placed into filtered culturing flask consisting of 50 mL of THB and then incubated overnight
for 18 hours at 37° C with 5% CO2 on a shaker. The Optical Density (OD) of the culture was
measured after each incubation phase by sampling 500 μL of culture with 500 μL of PBS and the
OD taken via spectrophotometer. The blank utilized consisted of 500 μL THB and 500 μL PBS
and referenced against any culture solutions measured. 7.5mL of glycerol was then added to 50
mL culture flask and vortexed creating a 15% glycerol solution. Aliquot 1 mL of culture solution
into cryogenic vials and placed into -80° C freezer for storage. When using stocks from storage,
remove 1 mL cryogenic vial of A66.1 sample from freezer and thawed in water bed at 37° C for
future use.
2.2 Mice Care and Scheduling
WT C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME). Mouse
were kept in specialized rodent facilities within McNulty Hall of Seton Hall University. Mice
were provided with water and food ad lib during the course of each experiment carried out in this
study. All mice utilized in experimentation were between the ages of 6-10 weeks old.
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All animal studies were reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC).

2.3 Living Viability Study and Immunization Experimentation
The following table provides the vaccination time table utilized.
Immunization
Day 1

Boost 1
Day 14

Boost 2
Day 28

Infection
Day 35

Table 1: Mouse Boost Schedule - This time frame was utilized during each study
that involved immunization with WT C57BL/6 mice

The living viability study examined the amount of A66.1 required for lethality of WT
C57BL/6 mice. The original stock concentration of A66.1 Streptococcus pneumonia is stored in
the freezer at -80° C until used and is at the concentration of 1 x 108 CFU. Upon use, a vial
containing stock cell lines was thawed in a water bath at 37 °C and then utilized for infections.
Doses were created by diluting down the original concentration of 1 x 108 CFU to 1 x 106, 5 x
105, and 1 x 105 CFU and then infecting each mouse intranasally with said concentrations. Mice
were inspected daily for observable symptoms and survival for a period of 15 days. If mice were
deemed unhealthy and displayed signs of extreme duress, lethal measures were taken to reduce
overall suffering.
Immunizations varied from study to study consisting of different doses administered
intranasally with PBS, PspA, CTB, or the combination of PspA with CTB. The first experiment
consisted of decreasing doses of PspA. The doses administered were as followed: 10 μg, 5 μg,
and 1 μg with PBS being the control and followed the boost schedule outline above. After day 35
infection, mice were observed and survivals counted.
2.4 Bacterial Burden
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After mice were infected, lung tissue was extracted from the mice and homogenized. A
portion of these samples were plated on Sheep Blood Agar and allowed to incubate over the
period of 18 hours at 37° C with 5% CO2. Plates were divided into subcategories which were
ten-fold dilutions from the original sample and titrated onto the blood agar plate. Upon
incubation, the colonies for each respective titration marked on each plate were counted to
determine the bacterial burden within each tissue sample.

2.5 Streptococcus pneumoniae Specific Antibody measurement
Specific antibody concentration titration measurements for Immunoglobulin G antibody
(IgG), and Immunoglobulin G antibody subclasses 1 and 2c (IgG1 and IgG2c respectively)
specific for A66.1 Streptococcus pneumoniae were examined via ELISA technique. Blood
samples were extracted submandibularly from immunized mice 2 days prior to infection.
ELISA plates were used for antibody titrations. Assay plates were coated with A66.1. To
do this, 1 mL cryogenic vial of A66.1 was added to 50 mL of THB and incubated at 37° C for 18
hours on a shaker. The culture was then centrifuged at 10 x G for a minute forming a pellet
consisting of the bacterial cells. The supernatant was removed and the pellet suspended in 200
mL of Carbonate Coating Buffer. Then coating solution was added to each well of the ELISA
assay plates and placed into the refrigerator at 4° C overnight until use. The plates were then
blotted and coated with blocking buffer (SuperBlock) and placed on a shaker at room
temperature for two hours. Plates were then blotted and washed with ELISA washing buffer
three times and blotted after each wash. Then blood serum from each respective group (Control,
PspA 5 μg, CTB 1 μg, PspA 5 μg + CTB 1 μg) was added to the diluent PBS to the first well of
each respective group creating a 1:100 titration each well. After which, each row consisted of a
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twofold dilution to the previous row until the final titration being 1:6400. Plates were placed on a
shaker for 90 minutes at 37° C. Plates were then washed and blotted three times. IgG, IgG1, or
IgG2c detection antibodies with conjugated Horse Radish Peroxidase (HRP) purchased from
Thermo Fisher© were added to the plate and placed on a shaker for 90 minutes at 37° C. After
which, 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was added to the plate and shaken for
ten minutes until color change. Plates were analyzed at 610nm via a spectrophotometer.

2.6 Cytokine measurement
The Enzyme Linked Immunosorbent Assay (ELISA) was used to count the cytokine
concentrations within the lungs and spleen in post infected mice. To do this, the lungs and spleen
were removed from the infected mice post mortem and placed into 10 mL falcon tube with 2mL
of Phosphate Buffer Saline (PBS). The tissue samples were then homogenized and placed into
micro centrifuge tubes to be stored at -20 ° C. On the first day, plates were coated in Capture
Antibody solution, which was specific to each cytokine being detected, and then incubated
overnight at 2-8° C. On the second day, plates were washed/blotted and then blocked with 10%
FBS at room temperature for 1 hour on a shaker. After blocking, plates were washed/blotted.
Samples were thawed and kept on ice as the desired amount of each group’s sample was
aliquoted out. Lung samples were diluted down to 1:10 concentration of the original sample
when applied to plate. Plate incubated at room temperature for 2 hours on shaker. Detection
antibody for the specific cytokine was then added to the plates and incubated at room
temperature for 1 hour. Next, Avidin-HRP was added to the wells and incubated for 30 minutes.
Then, TMB substrate was added in and incubated in the dark for between 20-30 minutes until
color change. The final step was the addition of stop solution. Plates were read with a
spectrophotometer at 450 nm and 570 nm. The 570 nm absorbance values were subtracted from
18

the 450nm absorbance values. All plates were washed 4 times in between steps until after the
addition TMB substrate step.

2.6 Statistical Analysis
The Log-Rank (Mantel-Cox) test was used for survival curves using the GraphPad Prizm
4 software.
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3. Results

3.1 Determining Living Viability of WT C57BL/6
Three groups of five WTC57BL/6 mice were infected intranasally at various titrated
doses of A66.1 Streptococcus Pneumoniae. The three concentrations were 1x106 CFU, 5x105
CFU, and 1x105 CFU. The purpose of this experiment was to determine the lowest dose required
to terminate 100% of mice in a group of five. Mice were monitored for 15 days. All mice died at
1.0 x106 CFU, 80% of mice died at 5.0 x105 CFU, and all mice survived at 1.0 x105 CFU. This
experiment concluded that the lethal dose was around 5.0 x105 CFU and thus all further
infections would use the same dose.
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Figure 2: Survival Study- After eight days of monitoring with no change in status:
All five mice died at the concentration of 1x106 CFU, four of the mice died at 5x105
CFU leaving one survivor, and none of the mice died at 1x105 CFU. No change in
survival rate was observed after 15 days.
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3.2 PspA and CTB titrations
3.2.1 PspA Titration
From determining the lethal dose of A66.1 to C57BL/6 WT mice, next step of the study
was to determine the dosage of PspA and CTB required to effectively immunize and protect
C57BL/6 WT mice from a lethal dose of A66.1 at 5.0 x 105 CFU. The initial objective was to
titrate the PspA and establish the dose required to effectively protect C57BL/6 mice. 1 μg, 5 μg,
and 10 μg against a control were used. PBS served as the control with 0% of the mice surviving.
At 1 μg, 20% of the mice survived. At 5 μg, 40% of the mice survived. At 10 μg we saw the
highest percentage with 100% of the mice surviving.
3.2.2 PspA + CTB titrations
Subsequently, we sought to determine if the use of the adjuvant CTB would increase the
effective protection of a midpoint survival dose of PspA which was determined to be
approximately 5 μg of PspA. To do this a dose of 1 μg of CTB was utilized. Four groups were
assigned with the following doses: Control (PBS), PspA (5μg), CTB (1μg), and PspA (5μg) +
CTB (1μg). Of the four groups, PspA + CTB had the highest survival rate at 100%. At 5 μg
PspA, 40% of the mice survived. Both PBS and 1 μg CTB had 0% survival.
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Figure 3: PspA Immunization Titration- Four groups of five WTC57BL/6 mice
were immunized with varying doses of Pmeumococcal Surface Protein A (PspA)
and boosted with the same initial dose on week 2 and 4 of the study. The groups
were then infected with A66.1 Streptococcus Pneumoniae at 5x105 CFU. All five
mice immunized with 10 μg PspA survived after eight days. Of the five mice
immunized with 5 μg PspA, two survived. Of the five mice immunized with 1 μg
PspA, one survived. Of the control group immunized with PBS, zero survived.
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CTB+PspA immunization

Percent survival

100

PBS
PspA (5μg)
CTB (1µg)
CTB (1µg)+PspA (5μg)

80
60
40
20
0
0

5

10

15

20

Day post-infection
Figure 4: CTB + PspA Immunization - Four groups of five WTC57BL/6 mice
were immunized with the following doses: Control group with 20 μL PBS, group
dosed with only 5 μg PspA each, group dosed with 1 μg CTB only, group dosed
with 1μg CTB and 5 μg PspA. Each group was boosted with the same initial dose
on week 2 and 4 of the study. The groups were then infected with A66.1
Streptococcus Pneumoniae at 5x105 CFU. All five control mice died after 15 days of
observation. All five mice immunized with 1 μg CTB died. Two mice immunized
with 5 μg PspA survived and three died. All five mice immunized with 5 μg PspA
and 1 μg CTB survived.
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3.3 Bacterial Burden in Post infected mice
Samples were titrated on Blood Agar plates and allowed to incubate over the period of 18
hours. Mice immunized with PBS, CTB(1μg), and PspA(5μg) exhibited colony growth up to
1.0x106 compared to PspA(5μg) + CTB (1μg) which exhibited no colony growth on any
titration.
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Figure 5: Bacterial Burden - Four groups of five WTC57BL/6 mice were
immunized with the following doses: Control group with 20 uL PBS, group dosed
with only 5 μg PspA each, group dosed with 1 μg CTB only, group dosed with 1μg
CTB and 5 μg PspA and boosted twice. After two days of infection, the lungs were
extracted from the mice, homogenized, and then plated at decreasing titrations. The
lungs of mice immunized with PBS, CTB(1μg), and PspA(5μg) exhibited colony
growth up to 1.0x106 where as PspA(5μg) + CTB (1μg) exhibited small growth.

26

3.4 Antibody titres in pre-infection C57BL/6 Mice
After immunizations with PspA and CTB, our aim was to determine the antibody levels
of IgG targeting A66.1 Streptococcus pneumoniae within WT C57BL/6 mice. Four groups of
mice followed the same protocols highlighted in section 3.2.2 of the PspA and CTB study. Prior
to infection, blood samples were taken from the mice and Antibody titrations created in
conjunction with the ELISA technique. Results found that of the four groups (PBS, PspA, CTB,
and PspA + CTB) the vaccine/adjuvant combination of PspA + CTB resulted in the greatest
concentrations of IgG, IgG1, and IgG2c. Sample group PspA demonstrated the second highest
levels
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Figure 6: IgG, IgG1, IgG2c Titration - Four groups of five WTC57BL/6 mice
were immunized with the following doses: Control group with 20 uL PBS, group
dosed with only 5 μg PspA each, group dosed with 1 μg CTB only, group dosed
with 1μg CTB and 5 μg PspA and boosted twice. Two days before infection, blood
was extracted submandibularly from three of the five mice of each group and
pooled. Three separate ELISAs was performed on each of the groups to determine
the antibody concentrations of IgG, IgG1, and IgG2c specific for A66.1. In all cases,
PspA (5μg) + CTB (1μg) exhibited the highest concentration and PspA (5μg)
exhibiting some levels of antibody. PBS and CTB exhibited no significant
production of antibody.
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3.5 Cytokine Concentrations in post-infection C57BL/6 Mice
For the last portion of this study, we wanted to establish the cytokine concentrations
within immunized mice after infection. Four groups of mice followed the same protocols
highlighted in section 3.2.2 of the PspA and CTB study. Post infection, lung tissue samples were
taken from the mice and homogenized. ELISA technique was used to determine the cytokine
concentrations of IL-2, IL-4, IL-6, TNF-α, and INF-γ in all four groups of mice. Results found
that of the four groups (PBS, PspA, CTB, and PspA + CTB) the vaccine/adjuvant combination of
PspA + CTB resulted in the greatest concentrations of IL-2 and INF-γ and the lowest
concentration of TNF-α and IL-6. IL-4 concentrations were relatively even throughout all four
groups.
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Figure 7: Cytokine INF-γ, IL-2, and IL-4 Concentrations Post-Infection:
Four groups of five WTC57BL/6 mice were immunized with the following
doses: Control group with 20 uL PBS, group dosed with only 5 μg PspA each,
group dosed with 1 μg CTB only, group dosed with 1μg CTB and 5 μg PspA
and boosted twice. Blood samples were then taken submandibulararly two days
post infection. Group PspA+CTB had the highest concentrations of IL-2 and
INF-y at approximately 1500 pg/mL and 130 pg/mL respectively. PspA had the
second highest with approximately 1000 pg/mL and 70 pg/mL. All groups had
no significant difference in IL-4 concentrations.
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Figure 8: Cytokine TNF-α and IL:-6 Concentrations Post-Infection: Four
groups of five WTC57BL/6 mice were immunized with the following doses:
Control group with 20 uL PBS, group dosed with only 5 μg PspA each, group
dosed with 1 μg CTB only, group dosed with 1μg CTB and 5 μg PspA and
boosted twice. Sample group PspA +CTB had significantly lower
concentrations of IL-6 and TNF-α compared to the remaining groups.
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4. Discussion
Analysis of our findings concluded that the subunit vaccine PspA with CTB was able to
successfully protect mice infected with lethal doses of A66.1 Streptococcus pneumoniae.
Initially, the lethal dosage of A66.1 for WTC57BL/6 had to be determined for the additional
survival studies. After establishing the protection conferred by the CTB as an adjuvant we next
sought to determine the immunological mechanisms involved in the protection involved. Both
cytokines and antibodies are key factors in humoral immunity which plays a key role in
protection against extracellular pathogens. By assessing these correlates of protection, we
concluded that mice immunized with PspA and CTB had the highest titres of immunoglobulin
subclass IgG specific for the A66.1 Streptococcus pneumoniae strain. Additionally, cytokine
concentrations suggested that immunized mice possessed higher concentrations of type-1
cytokines (IL-2, INF-γ) compared to control groups as well as lower pro-inflammatory cytokines
(TNF-α, IL-6). Essentially, mice immunized with PspA and CTB demonstrated a stronger
antibody and cytokine responses compared to mice immunized with PspA alone which offered
protection against lethal doses of A66.1 Streptococcus pneumoniae, thus highlighting the
effectiveness of CTB as a vaccine adjuvant.
The first portion of experiments aims to determine the dosage of A66.1 Streptococcus
pneumoniae required for lethality in WT C57BL/6 mice. At a dosage of 1 x 106 CFU A66.1, all
of the C57BL/6 mice died after two days while all of the mice survived with the dosage of 1 x
105 CFU A66.1 indicating that the LV50 or Living viability of half the mice would be between
these two values. At the dosage of 5 x 105 CFU A66.1, four of the five mice had died allowing us
to consider it as the lethal dose for WT C57BL/6 mice. This dose was then utilized throughout
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the study in an effort to assess the effectiveness of PspA as a subunit vaccine and the effect CTB
has as a mucosal vaccine adjuvant.
The survival study includes the subunit vaccine PspA in order to determine if it alone is
viable as an effective vaccine strategy against Streptococcus pneumoniae and at what dosage is
there a significant increase in mouse survival against the control. The PspA titration survival
study (Figure 3) indicates that PspA provided protection for the WT C57BL/6 mice against lethal
doses of A66.1 with 10 μg of PspA resulting in highest survival. With only PspA mouse groups
surviving, this coincides with the premise that PspA exists on the surface of A66.1 and that
administering it was able to elicit an immune response within mice and form memory against
A66.1 (Bitsaktsis et al., 2011). It also evident that increased doses of PspA proportionally
increased immunogenicity resulting in higher levels of protection in mice at the highest doses
versus mice with lower doses of PspA. These results coincides with previous studies (Bitsaktsis
et al., 2011; Gor et al., 2005; Ferreira et al., 2009) on the ability of PspA as a vaccination in the
protection against A66.1 Streptococcus pneumoniae.
The last stage of the survival studies was the combination of PspA with the adjuvant
CTB. To reaffirm, adjuvants increase the immunogenicity of a vaccine eliciting a stronger
immune response towards the vaccine, ultimately increasing protection against a target pathogen.
This survival study (Figure 4) indicates that PspA (5μg) was able to protect 40% of WT
C57BL/6 mice against a lethal dose of 5x105 CFU A66.1 which correlates to findings seen
previously (Figure 3). However, the addition of only 1μg of CTB was able to significantly
increase the survival to 100% for all five mice. CTB was able to successfully increase the
immunogenicity of the PspA vaccine and synergistically improve the efficacy of the vaccine to
full protection of the entire sample population. Corresponding to findings found in previous
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literature (Baldauf, 2015; Bitsaktsis et al., 2009; Kono, 2011), CTB was able to increase
immunogenicity of 5 μg PspA to the effects seen with 10 μg of PspA seemingly through the
activation of TH-1 cells. As anticipated, CTB alone did not drive any protection against S.
pneumoniae challenge, indicating the non-specific mode of action of adjuvants.
To assess the antibody titres generated in mice following immunization, blood samples
were taken pre-infection as outlined in section 2.4 and the titres were measured by ELISA.
Streptococcus pneumoniae-specific IgG and its subclasses IgG1 and IgG2c were detected and
compared among the different experimental groups. These findings (Figure 6) conclude that
mice vaccinated with PspA+CTB displayed the highest titre of IgG, IgG1, and IgG2c versus the
other groups. The mouse group immunized with PspA alone was able to elicit antibody
production of the IgG isotype but its titres were significantly less than the concentrations found
in vaccine/adjuvant sample group. Data from the titres emphasize the importance of
immunogenicity that each dose has within the host and the ability of the vaccine to from memory
cells against Streptococcus pneumoniae. Ultimately, these results coincide with the survival
studies which concluded that PspA is able to elicit an immune response and facilitate
immunoglobulin production against A66.1 Streptococcus pneumoniae. Secondly, when PspA is
administered with the adjuvant CTB, the antibody production of IgG is over two fold that
compared to the levels found in the mouse group immunized with PspA alone. These findings
reinforce the hypothesis that CTB is able to increase the immunogenicity of PspA against A66.1
and thusly generate better protection via a TH-1 activation which coincides with the survival
study outlined in Figure 4. It is evident that increased antibody production specific towards
A66.1 induced by PspA and enhanced via CTB results in increased humoral immunity and
allowed for all mice to survive lethal doses.
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Progressively, it was determined if A66.1 was growing at a decelerated rate within
PspA+CTB immunized mice compared to the other mouse groups. The bacterial burden (Figure
5) determined that the control, CTB, and PspA groups both expressed elevated levels of A66.1
growth within the lungs after day two of post infection. Meanwhile, the PspA+CTB sample
group possessed very little to no growth within the lungs compared to the other sample groups.
Since PspA+CTB possessed the greatest immunogenicity compared to the other mouse groups,
the formation of memory was evident in the overall reduction in bacterial colonization within the
lungs. This indicates that immunological protection is evident and strongest within immunized
PspA+CTB mice which successfully prevented A66.1 growth within the lungs. This correlates
with the heightened presence of total IgG, IgG1, and IgG2c specific for A66.1 within the
PspA+CTB mouse groups.
The last portion of this study analyzes the cytokine concentrations within immunized
mouse samples and their role in the inflammatory response. On day two post infection, lung and
spleen tissue samples were extracted from the four mouse groups immunized with PBS, PspA,
CTB, and PspA+CTB. With Cytokines IL-2 and INF-γ, mouse group PspA+CTB (Figure 7)
possessed the largest concentrations amongst four groups while the PspA mouse group having
slightly higher levels over CTB and PBS. Both IL-2 and INF-γ play an integral role in immunity
by stimulating immunoglobulin production and inducing B cell proliferation through their
interaction with TH-1 and TH-2 cells thusly initiating IgG class switching for IgG2c and IgG1
respectively (Owen et al.,2009). As discussed in Figure 1, IgG2c is predominantly generated via
TH-1 activation which is generated via INF- γ. With cytokines TNF-α and IL-6, mouse group
PspA+CTB exhibited the lowest concentrations of pro-inflammatory cytokines. This coincides
with the known increase in immune response time via the presence of memory cells in order to
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elicit a faster immune response in order to clear out the target pathogen. As a result, proinflammatory cytokines are expected to be at lower concentrations compared to the other mouse
groups due to the increased immune response generated within PspA-CTB mice.
By connecting results of the viability studies in conjunction with bacterial burden,
antibody titers, and cytokine concentrations, it can be concluded that the C57BL/6 mice
immunized with PspA and adjuvant CTB possessed the strongest protection against A66.1
Streptococcus pneumoniae. Mouse group PspA+CTB exhibited the greatest increase in type-1
and type-2 related cytokine secretion levels of INF-γ and IL-2/IL-4 respectively along with the
greatest titers of IgG isotype and its subclasses IgG2c and IgG1. PspA+CTB also possessed the
lowest concentrations of TNF-α and IL-6 compared to other mouse groups indicating lowered
pro-inflammatory cytokine levels which correlates to the lowered A66.1 growth within the lungs
determined via the bacterial burden study. The cytokine IL-4 was equally distributed between all
four groups which was anticipated as all sample groups would exhibit a shift towards type-2
cytokine production against an extracellular A66.1 Streptococcus pneumoniae. PspA+CTB
exhibits with the highest concentration in type-1 cytokine INF-γ compared to all other mouse
groups which correlates to the largest titre of IgG isotype subclass IgG2c. This correlates to
findings with previous studies which have also shown that CTB is associated with elevated levels
of TH-1 proliferation and recruitment during immunizations (Bitsaktsis et al., 2009)
Future research will examine cross species protection against varying serotypes of
Streptococcus pneumoniae. For example, Serotype 3 strain ATCC 6303 Streptococcus
pneumoniae is another commonly utilized pneumococcal pneumoniae utilized in murine models
and tested against the PspA-CTB vaccine in the future. Cytokines IL-5 and IL-10 are also
considered for analysis for examining the shift between the innate immunity towards the humoral
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adaptive immunity and for their roles in generating TH-2 and TH-1 responses. Lastly, the
immunoglobulin isotype IgA, which is predominately associated with mucosal sited immunity,
would be examined for its potential increased titres within C57BL/6 mice immunized with PspA
and adjuvant CTB.
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